1. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67.
2. Ostir GV, Goodwin JS. High anxiety is associated with an increased risk of death in an older tri-ethnic population. J Clin Epidemiol 2006;59:534-540.
3. Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003;51:671-677.
4. Snowdon J, Day S, Baker W. Current use of psychotropic medication in nursing homes. Int Psychogeriatr 2006;18:241-250.
5. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-140.
6. Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006;20:143-151.
7. Friedman RA, Leon AC. Expanding the black box: depression, antidepressants, and the risk of suicide. N Engl J Med 2007;356:2343-2346.
8. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006;163:813-821.
9. Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007;81:899-902.
10. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
11. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch RA. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004;76:618-627.
12. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006;1:CD003491.
13. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD005593.
14. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379-397.
15. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine MEM-MD-12 Study Group. Meman-tine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a rando-mized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-89.
16. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;2):CD003154.
17. Rosenberg C, Lauritzen L, Brix J, Jorgensen JB, Kofod P, Bayer LB. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice. Psychopharmacol Bull 2007;40:63-73.
18. Wehmeier PM, Kluge M, Maras A, Riemann D, Berger M, Kohnen R, Dittmann RW, Gattaz WF. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. Pharmacopsychiatry 2005;38:13-16.
19. Oslin DW, Ten Have TR, Streim JE, Datto CJ, Weintraub D, DiFilippo S, Katz IR. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003;64:875-882.
20. Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 2008;28:32-38.